PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Recommendation of “Moderate Buy” by Analysts

PolyPid Ltd. (NASDAQ:PYPD) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.25.

A number of brokerages recently weighed in on PYPD. Citigroup reiterated a “market outperform” rating on shares of PolyPid in a report on Monday, December 1st. Roth Mkm reduced their price objective on PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a report on Monday, December 29th. Finally, HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of PolyPid in a research note on Wednesday, February 11th.

PolyPid Stock Performance

PolyPid stock opened at $4.22 on Friday. PolyPid has a 1 year low of $2.30 and a 1 year high of $5.12. The firm has a 50 day moving average price of $4.43 and a 200 day moving average price of $3.87. The company has a market cap of $67.10 million, a price-to-earnings ratio of -1.87 and a beta of 1.52.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). Sell-side analysts predict that PolyPid will post -1.79 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets boosted its position in shares of PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after buying an additional 3,500 shares during the period. HighTower Advisors LLC acquired a new position in PolyPid during the 4th quarter worth approximately $44,000. Jane Street Group LLC purchased a new position in PolyPid in the 4th quarter worth approximately $66,000. Lumbard & Kellner LLC acquired a new stake in PolyPid in the second quarter valued at approximately $135,000. Finally, XTX Topco Ltd raised its stake in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares during the period. 26.47% of the stock is owned by hedge funds and other institutional investors.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.